Literature DB >> 8750551

Botulinum toxin in the therapy of gustatory sweating.

A Schulze-Bonhage1, M Schroder, A Ferbert.   

Abstract

Three patients suffering from gustatory sweating following trauma to the preauricular region from a bullet wound or parotid gland surgery were treated by intracutaneous injection of botulinum toxin A. Within 2 weeks, gustatory sweating in the area injected completely ceased in all patients with no side-effects. The efficacy of treatment was confirmed by repeated Minor's iodine starch tests. So far, sweating has not recurred during a follow-up period of up to 8 months. Botulinum toxin appears to be a promising new drug for the treatment of this autonomic disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750551     DOI: 10.1007/bf02444005

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  Auriculotemporal syndrome; gustatory sweating due to misdirection of regenerated nerve fibers.

Authors:  W J GARDNER; J W MCCUBBIN
Journal:  J Am Med Assoc       Date:  1956-01-28

Review 2.  Therapeutic uses of botulinum toxin.

Authors:  J Jankovic; M F Brin
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

3.  New observations regarding the auriculotemporal syndrome.

Authors:  R F Daly
Journal:  Neurology       Date:  1967-12       Impact factor: 9.910

4.  [A study of the innervation of the sweat glands of the facial region].

Authors:  H Schliack; R Schiffter; H H Goebel; I Schiffter-Retzlaw
Journal:  Acta Anat (Basel)       Date:  1972

5.  Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia.

Authors:  B Poulain; S Mochida; U Weller; B Högy; E Habermann; J D Wadsworth; C C Shone; J O Dolly; L Tauc
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

6.  Sprouting of mammalian motor nerve terminals induced by in vivo injection of botulinum type-D toxin and the functional recovery of paralysed neuromuscular junctions.

Authors:  J X Comella; J Molgo; L Faille
Journal:  Neurosci Lett       Date:  1993-04-16       Impact factor: 3.046

7.  Frey's syndrome: treatment with botulinum toxin.

Authors:  C Drobik; R Laskawi
Journal:  Acta Otolaryngol       Date:  1995-05       Impact factor: 1.494

8.  Localised autonomic failure due to botulinum toxin injection.

Authors:  A C Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.

Authors:  T Binz; J Blasi; S Yamasaki; A Baumeister; E Link; T C Südhof; R Jahn; H Niemann
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

10.  Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.

Authors:  P Girlanda; G Vita; C Nicolosi; S Milone; C Messina
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

View more
  4 in total

1.  Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation.

Authors:  David J Keegan; Gerd Geerling; John P Lee; Glen Blake; J Richard Collin; Gordon T Plant
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

3.  Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.

Authors:  Shang Xie; Kan Wang; Tao Xu; Xue-Sheng Guo; Xiao-Feng Shan; Zhi-Gang Cai
Journal:  Cancer Med       Date:  2015-08-26       Impact factor: 4.452

Review 4.  Use of the SMAS flap for reconstruction of the parotid lodge.

Authors:  G Dell'Aversana Orabona; G Salzano; V Abbate; P Piombino; F Astarita; G Iaconetta; L Califano
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-12       Impact factor: 2.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.